02Mar 2025
Efficacy of Anti-PD1 Immunotherapy in Advanced Salivary Gland Cancer

Efficacy of Anti-PD1 Immunotherapy in Advanced Salivary Gland Cancer

The systematic review and analysis of 9 clinical trials and 4 retrospective studies explored the role of anti-PD1 and anti-CTLA4 immunotherapy in patients with advanced, recurrent, or metastatic salivary gland cancer (SGC). Of 473 patients, pembrolizumab or nivolumab were administered, showing partial responses in 19 patients and stable disease in 145. Though anti-PD1 therapy demonstrated potential safety and efficacy, the studies were limited by small sample sizes and heterogeneity among SGC histologies. Larger, prospective trials are needed to validate these findings.

  • #ent

Like

Save

Share